uploads/2018/10/lab-316553_1280.jpg

Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings

By

Updated

Thermo Fisher’s Q3 2018 earnings

Thermo Fisher Scientific (TMO) reported its third quarter of 2018 results today, October 24. It surpassed Wall Street analysts’ estimates for both EPS and revenue. Its non-GAAP EPS was $2.62, and its revenues were $5.92 billion. That compares to analysts’ EPS estimate of $2.55 on revenues of $5.7 billion.

The above chart compares TMO’s EPS and revenues since the first quarter of 2017.

Article continues below advertisement

Revenue trend in Q3 2018

Thermo Fisher reported 15.6% growth in revenues to $5.92 billion for the third quarter, compared to $5.12 billion in Q3 2017. The increase in revenues includes organic revenue growth of 10% followed by a 7% growth driven by acquisitions. Foreign exchange had a 1% negative impact on revenues.

Revenue growth was driven by strong performances across all segments, including Laboratory Products and Services, Analytical Instruments, Life Sciences Solutions, and Specialty Diagnostics.

Revenues for Laboratory Products and Services increased 28% to ~$2.47 billion, compared to $1.93 billion in Q3 2017.

Revenues for Life Sciences Solutions increased 9% to ~$1.5 billion in the third quarter, compared to $1.38 billion in Q3 2017.

Revenues for Analytical Instruments increased 12% to ~$1.33 billion in the third quarter, compared to $1.19 billion in Q3 2017.

Specialty Diagnostics reported revenue growth of 6% to $894 million for the third quarter, compared to $844 million in Q3 2017.

The iShares US Medical Devices ETF (IHI) holds 7.6% of its total investments in Thermo Fisher Scientific (TMO), 9.8% in Medtronic (MDT), 9.4% in Abbott Laboratories (ABT), and 5.2% in Stryker (SYK).

Advertisement

More From Market Realist